Apellis Presented P-III (GALE) Extension Study Results of Syfovre for Geographic Atrophy at ASRS 2023
Shots:
- The P-III study evaluating Syfovre in patients with GA secondary to AMD, following 30mos. of continuous treatment with Syfovre
- The results showed that Syfovre continues to show robust & increasing effects through 30mos. with both monthly & every-other-month (EOM) treatment, reduction in GA lesion growth & nonsubfoveal GA lesion (39% & 45% with monthly) and (32% & 33% with EOM) b/w 24 and 30mos. over sham arm
- The safety profile was consistent with prior reported P-III data, zero non-serious AEs of ischemic optic neuropathy were reported b/w 24 & 30mos. with 1 serious AEs of ION in the monthly group & no cases of endophthalmitis were seen. The rate of IOI was 0.26% per inj. among all Syfovre-treated patients in the P-III program
Ref: GlobeNewswire | Image: Apellis
Related News:- Apellis Presents P-III Studies (OAKS) and (DERBY) Results of Syfovre (pegcetacoplan) in Patients with Geographic Atrophy at ARVO 2023
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
